Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 9, 2022New England Journal of MedicineOpen Access

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJerald SadoffGGGlenda GrayAVAn Vandebosch

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Sadoff et al. (2022) studied this question.

synapsesocial.com/papers/69deb4ae7702a00918b0c8afhttps://doi.org/10.1056/nejmoa2117608
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1SARS-CoV-2 vaccine protection and deaths among US veterans during 20212021 · 264 citations
  2. 2US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 20212021 · 546 citations
  3. 3Covid-19 Vaccine Effectiveness in New York State2021 · 285 citations
  4. 4Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses2020 · 377 citations
  5. 5Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 20212021 · 156 citations